Combination of an EGFR blocker and a COX-2 inhibitor for the treatment of advanced cutaneous squamous cell carcinoma;Kombination eines EGFR-blockers mit einem COX-2-inhibitor für die behandlung des fortgeschrittenen kutanen plattenepithelkarzinoms

JDDG - Journal of the German Society of Dermatology

Volumn 6, Issue 12, 2008, Pages 1066-1069

  Jalili, Ahmad ^a,b   Pinc, Alice ^a   Pieczkowski, Friederike ^a   Karlhofer, Franz M ^a   Stingl, Georg ^a   Wagner, Stephan N ^a,b  

^a Universitatsklinik fur Dermatologie   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

Cetuximab; COX 2; EGFR; Squamous cell carcinoma

Indexed keywords

CELECOXIB; CETUXIMAB; CYCLOOXYGENASE 2 INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; TETRACYCLINE;

ADVANCED CANCER; AGED; ARTICLE; ASPIRATION PNEUMONIA; BIOPSY TECHNIQUE; CANCER RADIOTHERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG USE; DYSPHAGIA; ECHOGRAPHY; EXOPHTHALMOS; HUMAN; HUMAN CELL; HUMAN TISSUE; KARNOFSKY PERFORMANCE STATUS; LYMPH NODE; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; PARIETAL LOBE; PARONYCHIA; PAROTID GLAND; RASH; SKIN CARCINOMA; SKIN FISSURE; SQUAMOUS CELL CARCINOMA; STOMATITIS; TUMOR REGRESSION;

AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; HUMANS; MALE; PYRAZOLES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SKIN NEOPLASMS; SULFONAMIDES; TREATMENT OUTCOME;

EID: 57649108802     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/j.1610-0387.2008.06861.x     Document Type: Article

References (14)

1. Alam M, Ratner D : Cutaneous squamous-cell carcinoma. N Engl J Med 2001 344 : 975 983.
2. Fogarty GB, Conus NM, Chu J, McAr-thur G. Characterization of the expression and activation of the epidermal growth factor receptor in squamous cell carcinoma of the skin. Br J Dermatol 2007 156 : 92 98.
3. Ono M, Kuwano M. Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs. Clin Cancer Res 2006 12 : 7242 7251.
4. Buchanan FG, Wang D, Bargiacchi F, DuBois RN. Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem 2003 278 : 35451 35457.
5. Xu K, Shu HK. EGFR activation results in enhanced cyclooxygenase-2 expression through p38 mitogen-activated protein kinase-dependent activation of the Sp1/Sp3 transcription factors in human gliomas. Cancer Res 2007 67 : 6121 6129.
6. Pai R, Soreghan B, Szabo IL, Pavelka M, Baatar D, Tarnawski AS. Prostag-landin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 2002 8 : 289 293.
7. Lippman SM, Gibson N, Subbara-maiah K, Dannenberg AJ. Combined targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways. Clin Cancer Res 2005 11 : 6097 6099.
8. Gosney MA. Clinical assessment of elderly people with cancer. Lancet Oncol 2005 6 : 790 797.
9. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006 354 : 567 578.
10. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000 92 : 205 216.
11. Bernier J, Bonner J, Vermorken JB, Bensadoun RJ, Dummer R, Giralt J, Kornek G, Hartley A, Mesia R, Robert C, Sega-ert S, Ang KK. Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. Ann Oncol 2008 19 : 142 149.
12. Kwak EL, Clark JW, Chabner B. Targeted agents: the rules of combination. Clin Cancer Res 2007 13 : 5232 5237.
13. Sibilia M, Wagner EF. Strain-dependent epithelial defects in mice lacking the EGF receptor. Science 1995 269 : 234 238.
14. Lacouture ME, Melosky BL. Cutaneous reactions to anticancer agents targeting the epidermal growth factor receptor: a dermatology-oncology perspective. Skin Therapy Lett 2007 12 : 1 5.